Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
Stopped Funding was not acquired
Conditions
- Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Interventions
- DRUG: Abiraterone Acetate
- DRUG: Prednisone
- DRUG: Aromatase Inhibitor
Sponsor
British Columbia Cancer Agency
Collaborators